Zobrazeno 1 - 10
of 10
pro vyhledávání: '"David Paul Carbone"'
Autor:
David Paul Carbone, Saiama N. Waqar, Jamie E. Chaft, Mark G. Kris, Bruce E. Johnson, Jay M. Lee, Ignacio I. Wistuba, David Kwiatkowski, Paul Bunn, Katja Schulze, Ann Johnson, Evelise Brandao, Mark Awad, Karen L. Reckamp, Anne C. Chiang, Alan Nicholas, Valerie Rusch
Publikováno v:
Cancer Research. 83:CT215-CT215
Background LCMC3 (NCT02927301), an open-label, single-arm Phase 2 study to investigate neoadjuvant (neoadj) and adj atezo (anti-PD-L1) in patients (pts) with early-stage non-small cell lung cancer (NSCLC), met its primary endpoint with a 20% major pa
Autor:
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo-Dols, Jaafar Bennouna, Ying Cheng, Hideaki Mizutani, Alejo Lingua, Felipe Reyes, Niels Reinmuth, Juliana Janoski De Menezes, Jacek Jassem, Svetlana Protsenko, Kynan Feeney, Emmanuel De La Mora Jimenez, Shun Lu, Tom John, David Paul Carbone, Xiaoqing Zhang, Nan Hu, Martin Reck
Publikováno v:
Journal of Clinical Oncology. 40:LBA9026-LBA9026
LBA9026 Background: In CheckMate 9LA (NCT03215706), 1L NIVO + IPI combined with 2 cycles of chemo was shown to provide survival benefit vs chemo alone in pts with metastatic NSCLC. Here, we report updated efficacy and safety with a 3-year minimum fol
Autor:
Keita Miura, Takehito Shukuya, Ray Greenstein, Benjamin G Kaplan, Heather A. Wakelee, Kana Kurokawa, Kazuyuki Furuta, Junghee Suh, Ethan Sokol, David Paul Carbone, Kazuhisa Takahashi
Publikováno v:
Journal of Clinical Oncology. 40:9125-9125
9125 Background: Racial differences in morbidity and mortality of non-small cell lung cancer (NSCLC) have been demonstrated and some genomic alterations (e.g. EGFR) in NSCLC are known to differ according to race. However, studies have been limited in
Autor:
Kana Kurokawa, Takehito Shukuya, Ray Greenstein, Benjamin G Kaplan, Heather A. Wakelee, Keita Miura, Kazuyuki Furuta, Junghee Suh, Ethan Sokol, David Paul Carbone, Kazuhisa Takahashi
Publikováno v:
Journal of Clinical Oncology. 40:8587-8587
8587 Background: Thymic epithelial tumors (TETs), including thymic carcinomas and thymomas, are rare neoplasms arising in the mediastinum. Chemotherapy is still the mainstay of treatment and few therapeutic options are available for patients with adv
Autor:
Yuval Shaked, Michal Harel, Coren Lahav, Ben Yellini, Ella Tepper, Ido Wolf, Tatiana Harkovsky, Raya Leibowitz, Maya Gottfried, Mahmud Abu-Amana, Rivka Katzenelson, Abed Agbarya, Mor Moskovitz, Michal Lotem, Adva Levy-Barda, Alona Zer, Ina Koch, David Paul Carbone, Adam P. Dicker, Petros Christopoulos
Publikováno v:
Journal of Clinical Oncology. 40:e21132-e21132
e21132 Background: To date, predicting response to immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) patients is based on assessing PD-L1 levels in tumor biopsies. However, such assays are only moderately predictive. In a
Autor:
Joy Tang, Sarah A. Janse, David Paul Carbone, Peter G. Shields, Melisa L. Wong, Nicole A Arrato, Barbara L. Andersen, Carolyn J Presley
Publikováno v:
Journal of Clinical Oncology. 40:1538-1538
1538 Background: As more treatment options become available for advanced non-small cell lung cancer (NSCLC), oncologists still have difficulty predicting functional resiliency versus functional disability throughout treatment. Functional resiliency r
Autor:
Gary Edward Richardson, John J. Park, Michael J. Boyer, Martin Gutierrez, David Paul Carbone, Panayiotis Savvides, Pravin Kaumaya, Tanios S. Bekaii-Saab, Tri Guang Phan, Leslie Mi Ok Chong, Steven Cha, Nicholas Ede, Bonnie Nixon, Anthony J Good
Publikováno v:
Journal of Clinical Oncology. 40:e21134-e21134
e21134 Background: Therapies with monoclonal antibodies targeting PD-1 and its ligands are associated with remarkable outcomes and have revolutionized cancer treatment (Honey 2017). However, patients treated with PD-1/PD-L1 blockade may develop “a
Autor:
David Downs, Rob Weker, Melissa Lynne Johnson, Adrian G. Sacher, Marcus O. Butler, Hassane M. Zarour, Jeffrey S. Weber, Edward B. Garon, David Paul Carbone, Ann Dokus, Jessica Taylor, Arindam Dhar, Marilyn Metcalf, Cristina Messina, John Yonchuk, Kristin Blouch, Anne-Marie Martin
Publikováno v:
Journal of Clinical Oncology. 40:e13598-e13598
e13598 Background: Current clinical trial selection for patients with independent screening for each trial, results in high screen failure and limited options for ineligible patients. MDCI’s concept for patient screening centers around broad molecu
Autor:
Boris Sepesi, David Randolph Jones, Bryan F. Meyers, Jamie E. Chaft, Lynette M. Sholl, Yu Shyr, Karen Kelly, Jules Lin, Paul A. Bunn, John D. Minna, Valerie W. Rusch, Ignacio Ivan Wistuba, David J. Kwiatkowski, David Paul Carbone, Lynne D. Berry, Jay M. Lee, Khaled Tolba, Mark G. Kris
Publikováno v:
Journal of Clinical Oncology. 40:TPS8596-TPS8596
TPS8596 Background: Comprehensive genomic profiling (CGP) has transformed the care of patients with advanced non-small cell lung cancer (NSCLC), giving many patients access to precision targeted treatment and immunotherapy with remarkable improvement
Publikováno v:
Cancer Research. 79:4930-4930
Lung cancer management has been transformed by the discovery and effective targeting of driver mutations such as epidermal growth factor receptor (EGFR). Tyrosine Kinase Inhibitors (TKIs) that block EGFR kinase activity such as erlotinib and osimerti